Latest Breaking News On - Phylander pannell - Page 3 : comparemela.com

June 5, 2021 Share Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide, for long-term weight management. In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 pounds (15.3 kilograms). Participants lost weight steadily for 16 months before plateauing. In a comparison group getting dummy shots, the average weight loss was about 2.5%, or just under 6 pounds. “With existing drugs, you’re going to get maybe 5% to 10% weight reduction, sometimes not even that,” said Dr. Harold Bays, medical director of the Louisville Metabolic and Atherosclerosis Research Center. Bays, who is also the Obesity Medicine Association’s chief science officer, helped run studies of the drug.

United statesArchana sudhuPhylander pannellNovo nordisk victozaAtherosclerosis research centerDrug administrationObesity medicine associationNovo nordiskHarold baysLouisville metabolicAtherosclerosis researchHouston methodist hospitalஒன்றுபட்டது மாநிலங்களில்உடல் பருமன் மருந்து சங்கம்ஹரோல்ட் விரிகுடாக்கள்லூயிஸ்வில்லி வளர்சிதை மாற்ற